RT Journal Article
SR Electronic
T1 Pharyngeal carriage of inoculated recombinant commensal bacteria generates antigen-specific immunological memory
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.06.20093450
DO 10.1101/2020.05.06.20093450
A1 Laver, Jay R
A1 Gbesemete, Diane
A1 Dale, Adam P
A1 Pounce, Zoe C
A1 Webb, Carl N
A1 Roche, Eleanor F
A1 Berreen, Graham
A1 Belogiannis, Konstantinos
A1 Hill, Alison R
A1 Ibrahim, Muktar M
A1 Cleary, David W
A1 Pandey, Anish K
A1 Humphries, Holly E
A1 Allen, Lauren
A1 de Graaf, Hans
A1 Maiden, Martin C
A1 Faust, Saul N
A1 Gorringe, Andrew R
A1 Read, Robert C
YR 2020
UL http://medrxiv.org/content/early/2020/05/10/2020.05.06.20093450.abstract
AB The human nasopharynx is colonized by commensal bacteria and pathobionts, which comprise a complex microbial ecosystem capable of generating primary and secondary immune responses. Experimental intranasal infection of human adults with the commensal Neisseria lactamica results in safe, sustained colonization. Herein is described a novel technology to chromosomally transform N. lactamica with heterologous antigen, for the purpose of safe delivery to the mucosal surface and the generation of an antigen-specific immune response. N. lactamica was transformed to express the meningococcal vaccine antigen Neisseria Adhesin A (NadA) and was inoculated intranasally into humans at a dose of 105 colony-forming units. NadA-expressing N. lactamica colonized these individuals and was carried asymptomatically for 3 months. Colonization with NadA-expressing N. lactamica generated NadA-specific IgG-secreting plasma cells within 14 days of colonization and both NadA-specific IgG and NadA-specific IgG memory B cells within 28 days of colonization. NadA-specific IgG memory B cells circulate in the bloodstream of colonized participants for at least 90 days. Genetically transformed N. lactamica has the potential to be a safe bacterial vehicle to generate beneficial immune responses to a wide range of heterologous antigens during sustained pharyngeal carriage.Competing Interest StatementJ.R.L. and R.C.R. declare competing interests in the form of being ‘Inventors’ on University of Southampton Patent: WO2017103593A1. All other authors declare no competing interests.Clinical TrialNCT03630250Funding StatementThis work was funded by the UK Medical Research Council (MR/N013204/1: ‘A genetically modified nasopharyngeal commensal as a platform for bacterial therapy’, and MR/N026993/1: ‘Pathfinder: Experimental Human Challenge with Genetically Modified Commensals to Investigate Respiratory Tract Mucosal Immunity and Colonization’) with additional funding from the MRC Confidence in Concept Award and the Wessex Institute for Vaccines and Infectious Disease. Robert Read is an NIHR Senior Investigator (NF-SI-0617- 10010), Adam Dale is supported by the Wellcome Trust Research Training Fellowship (203581/Z/16/Z) and the work is supported by the National Institute for Health Research Southampton Biomedical Research Centre (IS- BRC-1215-20004).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe complete reference genome of parent strain Y92-1009 is available as published work and on GenBank (accession: CP019894.1). Other data supporting the findings of the study are available in this article and its Supplementary Information file, or from the corresponding author upon request.